News Briefs
August 26
✦ The FDA approved an additional indication for Jardiance (empagliflozin), allowing the drug to be used to “reduce the risk of cardiovascular death plus hospitalization for heart failure in adults with heart failure with reduced ejection fraction (HFrEF),” according to a press release from Boehringer Ingelheim and Eli Lilly and Co. According to an Aug. 18 press release, the drug was already approved to “lower blood sugar along with diet and exercise in adults with type 2 diabetes, reduce the risk of cardiovascular death in adults with type 2 diabetes who also have known cardiovascular disease, [and] reduce the risk of cardiovascular death and hospitalization for heart failure…in adults with heart failure.”
© 2023 MMIT
Related Posts
Meet Our Reporters
-
Angela Maas Managing Editor, RADAR on Specialty Pharmacy and Spotlight on Market Access
View Angela Maas's Profile -
Leslie Small Managing Editor, Health Plan Weekly and RADAR on Drug Benefits
View Leslie Small's Profile -
Lauren Flynn Kelly Managing Editor, RADAR on Medicare Advantage
View Lauren Flynn Kelly's Profile -
Peter Johnson Reporter, Health Plan Weekly and RADAR on Drug Benefits
View Peter Johnson's Profile -
Tim Casey Reporter, Health Plan Weekly and RADAR on Drug Benefits
View Tim Casey's Profile -
Carina Belles Reporter, RADAR on Medicare Advantage and Spotlight on Market Access
View Carina Belles's Profile -
Jinghong Chen Reporter, Health Plan Weekly and RADAR on Drug Benefits
View Jinghong Chen's Profile -
Jill Brown Kettler Executive Editor
View Jill Brown Kettler's Profile
